TIMP1 and Alzheimer disease: Tissue inhibitors of matrix metalloproteinase (TIMP-2) CSF levels were elevated in AD/VaD without CMBs (n = 27) compared with cognitively normal controls (n = 26) and AD/VaD patients with CMBs (n = 34), but no differences were found for TIMP-1 (41).